{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:42:06Z","timestamp":1791042126755,"version":"4.1.0"},"reference-count":40,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2012,9,6]],"date-time":"2012-09-06T00:00:00Z","timestamp":1346889600000},"content-version":"vor","delay-in-days":736,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Obesity"],"published-print":{"date-parts":[[2010,9]]},"abstract":"<jats:p>Preclinical evidence suggests that pharmacotherapy for obesity using combinations of agents targeted at distinct regulatory pathways may produce robust additive or synergistic effects on weight loss. This randomized placebo\u2010controlled trial examined the safety and efficacy of the amylin analogue pramlintide alone or in combination with either phentermine or sibutramine. All patients also received lifestyle intervention. Following a 1\u2010week placebo lead\u2010in, 244 obese or overweight, nondiabetic subjects (88% female; 41 \u00b1 11 years; BMI 37.7 \u00b1 5.4 kg\/m<jats:sup>2<\/jats:sup>; weight 103 \u00b1 19 kg; mean \u00b1 s.d.) received placebo subcutaneously (sc) t.i.d., pramlintide sc (120 \u00b5g t.i.d.), pramlintide sc (120 \u00b5g t.i.d.) + oral sibutramine (10 mg q.a.m.), or pramlintide sc (120 \u00b5g t.i.d.) + oral phentermine (37.5 mg q.a.m.) for 24 weeks. Treatment was single\u2010blind for subjects receiving subcutaneous medication only and open\u2010label for subjects in the combination arms. Weight loss achieved at week 24 with either combination treatment was greater than with pramlintide alone or placebo (<jats:italic>P<\/jats:italic> &lt; 0.001; 11.1 \u00b1 1.1% with pramlintide + sibutramine, 11.3 \u00b1 0.9% with pramlintide + phentermine, \u22123.7 \u00b1 0.7% with pramlintide; \u22122.2 \u00b1 0.7% with placebo; mean \u00b1 s.e.). Elevations from baseline in heart rate and diastolic blood pressure were demonstrated with both pramlintide + sibutramine (3.1 \u00b1 1.2 beats\/min, <jats:italic>P<\/jats:italic> &lt; 0.05; 2.7 \u00b1 0.9 mm Hg, <jats:italic>P<\/jats:italic> &lt; 0.01) and pramlintide + phentermine (4.5 \u00b1 1.3 beats\/min, <jats:italic>P<\/jats:italic> &lt; 0.01; 3.5 \u00b1 1.2 mm Hg, <jats:italic>P<\/jats:italic> &lt; 0.001) using 24\u2010h ambulatory monitoring. However, the majority of subjects receiving these treatments remained within normal blood pressure ranges. These results support the potential of pramlintide\u2010containing combination treatments for obesity.<\/jats:p>","DOI":"10.1038\/oby.2009.478","type":"journal-article","created":{"date-parts":[[2010,1,21]],"date-time":"2010-01-21T15:37:20Z","timestamp":1264088240000},"page":"1739-1746","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":86,"title":["Enhanced Weight Loss Following Coadministration of Pramlintide With Sibutramine or Phentermine in a Multicenter Trial"],"prefix":"10.1002","volume":"18","author":[{"given":"Louis J.","family":"Aronne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy E.","family":"Halseth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen M.","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry Z.","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,9,6]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0803649"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1037\/0022-006X.71.6.1084"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.3310\/hta8210"},{"key":"e_1_2_8_5_2","first-page":"397","article-title":"Beneficial health effects of modest weight loss","volume":"16","author":"Goldstein DJ","year":"1992","journal-title":"Int J Obes Relat Metab Disord"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-789X.2004.00127.x"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.299.3.316"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-789X.2008.00520.x"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-143-5-200509060-00013"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1124\/pr.59.2.2"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200565100-00006"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-007-0061-0"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-0029"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464130-00003"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2006.04.001"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1210\/en.2006-0393"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1109951"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.2174\/157339908784220741"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature05026"},{"key":"e_1_2_8_20_2","first-page":"341","volume-title":"Integrated neurohormonal approaches to the treatment of obesity: the amylin agonist pramlintide and its interactions with leptin and PYY signaling pathways","author":"Roth JD","year":"2008"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1053\/meta.2001.24917"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0706473105"},{"key":"e_1_2_8_23_2","first-page":"269","article-title":"The effect and safety of an ephedrine\/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial","volume":"16","author":"Astrup A","year":"1992","journal-title":"Int J Obes Relat Metab Disord"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1984.00350180055008"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2008.91"},{"key":"e_1_2_8_26_2","volume-title":"The LEARN Program for Weight Management","author":"Brownell KD","year":"2004"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1983.tb09716.x"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000154900.76284.F6"},{"key":"e_1_2_8_29_2","unstructured":"Adipex\u2010P.Prescribing Information. Gate Pharmaceuticals: Sellersville PA 2005."},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-2003"},{"key":"e_1_2_8_31_2","unstructured":"Meridia.Prescribing Information. Abbott Laboratories: Chicago IL 2007."},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00217.2007"},{"issue":"1","key":"e_1_2_8_33_2","first-page":"S63","article-title":"Long term weight loss from a dose optimization study with zonisamide SR and bupropion SR","volume":"16","author":"Landbloom R","year":"2008","journal-title":"Obesity"},{"key":"e_1_2_8_34_2","first-page":"A95","article-title":"One\u2010year treatment with VI\u20100521 in type 2 diabetes demonstrates continued glycemic improvement and weight loss","volume":"68","author":"Garvey WT","year":"2009","journal-title":"Diabetes"},{"key":"e_1_2_8_35_2","volume-title":"Lorcaserin reduces body weight in obese and overweight subjects: behavioral modification and lorcaserin for overweight and obesity management, the BLOOM trial","author":"Smith SR","year":"2009"},{"issue":"1","key":"e_1_2_8_36_2","first-page":"A10","article-title":"Naltrexone+bupropion combination causes significant weight loss: a 56\u2010week phase 3 study","volume":"58","author":"Wadden T","year":"2009","journal-title":"Diabetes"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0801889"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.5588.352"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.9.994"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39385.413113.25"},{"key":"e_1_2_8_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehm217"}],"container-title":["Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Foby.2009.478","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Foby.2009.478","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1038\/oby.2009.478","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T16:25:53Z","timestamp":1697559953000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1038\/oby.2009.478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["10.1038\/oby.2009.478"],"URL":"https:\/\/doi.org\/10.1038\/oby.2009.478","archive":["Portico"],"relation":{},"ISSN":["1930-7381","1930-739X"],"issn-type":[{"value":"1930-7381","type":"print"},{"value":"1930-739X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9]]},"assertion":[{"value":"2012-09-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}